NCT07499362招募中2 期
Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年3月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Safety Run-In Cohort: Number of Participants with Dose Limiting Toxicity (DLT)-like events
研究概览
简要总结
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
详细描述
The purpose of this study is to assess the tolerability, pharmacokinetics (PK), efficacy, and safety of pimicotinib in Japanese participants with TGCT in two cohorts: Safety Run-in and Expansion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Japanese participants with a diagnosis of TGCT that has been histologically confirmed at the local laboratory and is unresectable (that is [i.e.] it is located in a complex anatomical site, extensively invasive, and cannot be completely resected; or a surgical operation may cause dysfunction or serious complications). Symptomatic disease because of active TGCT, defined as a worst pain of greater than or equal to [>=] 4 within 2 weeks prior to enrollment (based on scale of 0 to 10, with 10 representing "pain as bad as you can imagine"), and/or a worst stiffness of >= 4 within 2 weeks prior to first dose of pimicotinib (based on a scale of 0 to 10, with 10 representing "stiffness as bad as you can imagine")
- •Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to [<=] 1
- •Participants with adequate hepatic, renal hematologic functions
- •Other protocol defined inclusion criteria may apply
排除标准
- •Known additional malignancy that required active treatment and may affect the participant's participation in the study or affect the outcome of the study as assessed by the Investigator. Exceptions include cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and other carcinoma in situ
- •Serious gastrointestinal bleeding within 3 months of first dose of pimicotinib or factors that significantly affected the absorption of oral drug, such as inability to take oral medication or significant nausea and vomiting, malabsorption, external bile duct drainage, massive small-bowel resection, etc.
- •Impaired cardiac function or clinically significant cardiac disease, including any one of the following: New York Heart Association (NYHA) class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure; prolongation of the rate corrected QT interval based on repeated demonstration of QT interval corrected using Fridericia's formula (QTcF) greater than (>) 480 milliseconds (ms), or history of long QT interval corrected (QTc) syndrome; Left ventricular ejection fraction (LVEF) less than (<) 50 percent (%) or below the lower limit of normal, whichever is higher
- •Cerebrovascular accident/stroke (within 6 months of first dose of pimicotinib)
- •Other protocol defined exclusion criteria may apply
研究组 & 干预措施
Safety Run-In followed by Expansion Cohort: Pimicotinib
Experimental
干预措施: Pimicotinib (Drug)
结局指标
主要结局
Safety Run-In Cohort: Number of Participants with Dose Limiting Toxicity (DLT)-like events
时间窗: Day 1 up to Day 28 of Cycle 1 (each cycle is of 28 days)
Safety Run-In Cohort: Pharmacokinetic (PK) Plasma Concentration of Pimicotinib
时间窗: Pre-dose up to 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is of 28 days)
Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee
时间窗: Time from first study treatment until progressive disease or death, assessed up to approximately 2 years
次要结局
- Objective Response (OR) According to Tumor Volume Score (TVS) as Assessed by Independent Review Committee (IRC)(Time from first study treatment until progressive disease or death, assessed up to approximately 2 years)
- Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by Investigator(Time from first study treatment until progressive disease or death, assessed up to approximately 2 years)
- Mean Change from Baseline in Range of Motion (ROM) at Week 25(Baseline, Week 25)
- Mean Change from Baseline in Worst-Stiffness-Numeric Rating Scale (NRS) Score at Week 25(Baseline, Week 25)
- Mean Change from Baseline in Brief Pain Inventory (BPI)- Worst-Stiffness-Numeric Rating Scale (NRS) Score at Week 25(Baseline, Week 25)
- Mean Change from Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Physical Functioning Score at Week 25(Baseline, Week 25)
- Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee(Time from first documentation of objective response until progressive disease (PD) or death, assessed approximately up to 2 years)
- Duration of Response (DOR) According to Tumor Volume Score (TVS) as Assessed by Independent Review Committee (IRC)(Time from first documentation of objective response until progressive disease (PD) or death, assessed approximately up to 2 years)
- Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by Investigator(Time from first documentation of objective response until progressive disease (PD) or death, assessed approximately up to 2 years)
- Mean Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Health Scale Score at Week 25(Baseline, Week 25)
- Mean Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score at Week 25(Baseline, Week 25)
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events(Time from first study treatment, assessed up to approximately 2 years)
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pimicotinib(Pre-dose up to 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is of 28 days))
- Accumulation Ratio for Maximum Observed Plasma Concentration [Racc(Cmax)] of Pimicotinib After Repeated Administration(Pre-dose up to 24 hours post-dose on Cycle 1 Day 15 (each cycle is of 28 days))
- Accumulation Ratio of Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours (AUC0-24) of Pimicotinib After Repeated Administration(Pre-dose up to 24 hours post-dose on Cycle 1 Day 15 (each cycle is of 28 days))
- Plasma Concentration Observed at the End of a Dosing Interval Immediately before Next Dosing (Ctrough) of Pimicotinib(Pre-dose on Cycle 1 Day 15 (each cycle is of 28 days))
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
1 期
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian CancerNCT07273396Seoul National University Hospital53
尚未招募
1 期
QLS5132 Combination Therapy in Advanced Solid TumorsOvarian CancerNCT07453394Qilu Pharmaceutical Co., Ltd.626
招募中
1 期
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal SprayNCT07259538VivaVision Biotech, Inc60
尚未招募
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese SubjectsDeliriumNCT07422142Kunming Pharmaceuticals, Inc.54
进行中（未招募）
1 期
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.Healthy VolunteerNCT07514260AbbVie24